{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T07:54:31Z","timestamp":1790927671024,"version":"4.1.0"},"reference-count":0,"publisher":"S. Karger AG","license":[{"start":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:00:00Z","timestamp":1790640000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"},{"start":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:00:00Z","timestamp":1790640000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncol Res Treat"],"abstract":"<jats:p>Introduction: Patient-reported outcomes (PROs), particularly health-related quality of life (HRQoL) and treatment-related side effects, are crucial for guiding treatment in advanced renal cell carcinoma (aRCC). We report longitudinal PRO data prospectively collected in a real-world aRCC setting during the targeted therapy era. Methods: Patients with aRCC were enrolled in the prospective, observational, multicenter PRO Kidney cohort study (NCT02537743) from 2015-2018. PROs were assessed tablet-based from baseline up to 24 months using validated instruments (NCCN FACT FKSI 19, FACIT Fatigue), and custom questions on RCC-\/treatment-specific symptoms (IOAE) and daily life impact (IODAYA). Descriptive statistics were used, except for time-to-deterioration (TTD) analysis. Results: Of 98 patients signing informed consent, 90 with at least one completed PRO questionnaire were included in the full analysis set; 80 with baseline questionnaires were analyzed for HRQoL. Median age was 68 years; 78.9% (n=71) presented with clear-cell histology and 44.4% (n=40) were at intermediate MSKCC risk. The most frequently used first-line treatments were pazopanib (56.7%; n=51) and sunitinib (23.3%; n=21). Clinically relevant deterioration in HRQoL was observed in 52.5% (n=42) of patients within six months (median TTD 5.1 months, 95%CI 2.9-7.0). Treatment was associated with fatigue, nausea, diarrhea and altered taste, independent of treatment regimen. Most patients reported being content with their HRQoL and were able to continue with their day-to-day activities. Discussion: Despite treatment-related side effects and HRQoL deterioration in some patients, most maintained daily functioning and reported acceptable overall HRQoL, suggesting that tyrosine kinase inhibitor monotherapy may remain a valuable option, particularly for those with contraindications to immunotherapy.<\/jats:p>","DOI":"10.1159\/ort\/aecag007","type":"journal-article","created":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T19:27:17Z","timestamp":1789673237000},"source":"Crossref","is-referenced-by-count":0,"title":["Comprehensive quality of life assessment in advanced renal cell carcinoma: Final results of the PRO Kidney study"],"prefix":"10.1159","author":[{"given":"Tilman","family":"Kirste","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Scheffler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralf","family":"Eckert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henning","family":"Pelz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lothar","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oswald","family":"Burkhard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaqueline","family":"Rauh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thorsten","family":"Werner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harald-Robert","family":"Bruch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus-Ulrich","family":"D\u00e4\u00dfler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harald","family":"Junius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnd","family":"Nusch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Hamm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Chiabudini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1015-9624","authenticated-orcid":false,"given":"Karin","family":"Potthoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"127","published-online":{"date-parts":[[2026,9,29]]},"container-title":["Oncology Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/karger.com\/article-pdf\/doi\/10.1159\/ort\/aecag007","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T07:18:23Z","timestamp":1790925503000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/ort\/aecag007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,29]]},"references-count":0,"URL":"https:\/\/doi.org\/10.1159\/ort\/aecag007","archive":["Portico"],"relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.6084\/m9.figshare.33963202","asserted-by":"subject"}]},"ISSN":["2296-5270","2296-5262"],"issn-type":[{"value":"2296-5270","type":"print"},{"value":"2296-5262","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,29]]}}}